Novartis (NVS) has released an update.
Novartis AG has announced FDA approval of Kisqali (ribociclib) for adjuvant treatment of specific early breast cancer (EBC) patients at high risk of recurrence, showing a 25% reduction in recurrence risk compared to endocrine therapy alone. This approval broadens the treatment scope for more patients, including those with node-negative disease. Novartis emphasizes the importance of this advancement in potentially preventing cancer recurrence in EBC survivors.
For further insights into NVS stock, check out TipRanks’ Stock Analysis page.
